Sage Therapeutics Stock News

Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at $15,900 for an entire 14-day treatment course.

Third-quarter figures were not inspiring to investors. The biotech missed rather badly on both the top and bottom lines.

SAGE Therapeutics, Inc. (NASDAQ:SAGE ) Q3 2023 Earnings Conference Call November 7, 2022 8:00 AM ET Company Participants Ashley Kaplowitz - Director, IR Barry Greene - President, CEO & Director Christ

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $2.81 per share versus the Zacks Consensus Estimate of a loss of $2.64. This compares to loss of $2.31 per share a year ago.

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a l

Sage Therapeutics, Inc. received FDA approval along with Biogen for its drug ZURZUVAE for the treatment of postpartum depression, with a planned launch in Q4 2023. The company has several ongoing stud

Shares of Sage Therapeutics Inc jumped 5% in premarket trading following the announcement that the US Food and Drug Administration (FDA) has granted orphan-drug status to SAGE-718, a treatment for H

The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regarding FDA app

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will

The plunge in Sage's (SAGE) shares comes after the FDA declined to approve Zurzuvae in major depressive disorder indication, citing management to conduct more clinical studies.

SAGE Therapeutics (NASDAQ:SAGE) has announced a major reorganization, including laying off about 40% of its workforce, after the US Food & Drug Administration rejected its drug application for major d

Sage Therapeutics said on Thursday it would cut its workforce by about 40%, weeks after the U.S. health regulator declined to approve its drug to treat major depressive disorder.

The Food and Drug Administration only granted partial approval to zuranolone this month. Sage is an unprofitable business, so it's a big blow that ensures the company's operations remain in the red fo

The FDA approved Zurzuvae for postpartum depression but not for major depressive disorder. Sage saw revenues and net losses climb in the second quarter.